NEWS
To Treat The New Crown, This Medicine Is Cheap And Easy To Use!As the first oral anti-new coronavirus drug molnupiravir (MK-4482, EIDD-2801), the report attracted attention. This drug candidate from Merck has achieved positive results in the interim analysis of t
- Velipanib is a PARP inhibitor for the treatment of ovarian cancer
The PARP retarder Stepani Veliparib has entered everyone's attention. This type of drug can treat various types of ovarian diseases, and can significantly improve the patient's objective response rate
- 山东四环药业股份有限公司创新药物高端生产制造基地项目环境影响评价第二次信息公示
- Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-r
The European Commission has granted marketing authorisation in the European Union (EU) for Nubeqa® (darolutamide), an oral androgen receptor inhibitor (ARi). The approval is based on Phase III ARAMIS
- Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some
- China smacks 48 officials, including ex-FDA official, in Changsheng vaccine scandal
China’s anticorruption authorities have punished 48 officials found responsible for the Changchun Changsheng Life Sciences vaccine scandal that provoked public outrage last summer.